CoChat

Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab

Tookman, A. J., Jones, C. L., DeWitte, Mark, Lodge, P. J. · 2008 · Supportive Care in Cancer

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Goals of work The objective of this study was to determine the effect of infliximab, an antitumor necrosis factor alpha (TNFalpha) antibody, on fatigue in patients with advanced cancer.Materials and methods This was a pilot study undertaken in a specialist palliative care unit. Seventeen eligible outpatients were enrolled in this study. Infliximab 5 mg/kg was administered intravenously at baseline and if there was observable clinical benefit, every 4 weeks thereafter until clinical benefit was lost. The primary outcome measure assessing subjective functional improvement was the change in fatigue severity scale (FSS) score at 4 weeks following an infliximab infusion. Secondary outcome measures of subjective functional improvement that were assessed 4 weeks after each infliximab infusion included changes in Karnofsky performance status (KPS), hospital anxiety and depression scale (HADS) score, anxiety and depression subscores, and appetite visual analogue scale. Clinical laboratory assessments were C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), TNFalpha, interleukin-6, and leptin concentrations.Main results At week 4, 9 of 14 patients improved in FSS, 3 of 15 improved in KPS, 7 of 15 improved in total HADS and the majority had modest improvements in serum CRP, ESR, or leptin concentrations. Case studies of six patients with overall improvement are described in detail. Five serious adverse events occurred; two were serious infections possibly related to treatment.Conclusions A subgroup of patients in this small pilot study demonstrated uniform subjective/clinical benefit. We were not able to identify any predictors of this response; a larger, controlled study may reveal more information.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00520-008-0429-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Coleman MP, Babb P, Damiecki P, Grosclaude P et al (1999) Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS Region. Studies in Medical and Population Subjects No 61. The Stationery Office, London

Cited by

See all 43

Metadata

Authors
Tookman, A. J., Jones, C. L., DeWitte, M., & Lodge, P. J.
Affiliations
The Royal Free Hospital (GB)
Corresponding author
Tookman, A. J.
Venue
Supportive Care in Cancer
Published
2008-05-21
Volume
16
Issue
10
Pages
1131-1140
ISSN
  • 0941-4355 (ISSN-L)
  • 1433-7339
OpenAlex
W1996558108
Cited by
41
References
22
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
1.06
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Supportive Care in Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
cancer-related fatigue, infliximab, anti-TNF therapy, advanced cancer, palliative care, Fatigue Severity Scale, Karnofsky performance status, anxiety and depression, C-reactive protein, interleukin-6, leptin, adverse events
MeSH terms
Infliximab, Adult, Aged, Antibodies, Monoclonal, Fatigue, Female, Hospices, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasms, Palliative Care, Pilot Projects, Prospective Studies, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.